Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists

Latest ORBIMED ADVISORS LLC Stock Portfolio

$5.06Billion– No. of Holdings #108

ORBIMED ADVISORS LLC Performance:
2024 Q2: -2.14%YTD: 12.6%2023: 1.22%

Performance for 2024 Q2 is -2.14%, and YTD is 12.6%, and 2023 is 1.22%.

About ORBIMED ADVISORS LLC and 13F Hedge Fund Stock Holdings

ORBIMED ADVISORS LLC is a hedge fund based in NEW YORK, NY. On 29-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $18.3 Billions. In it's latest 13F Holdings report, ORBIMED ADVISORS LLC reported an equity portfolio of $5.1 Billions as of 30 Jun, 2024.

The top stock holdings of ORBIMED ADVISORS LLC are SVA, LLY, EWTX. The fund has invested 6.7% of it's portfolio in SINOVAC BIOTECH LTD and 6% of portfolio in ELI LILLY & CO.

The fund managers got completely rid off ALPINE IMMUNE SCIENCES INC (ALPN), ESPERION THERAPEUTICS INC NE (ESPR) and PRAXIS PRECISION MEDICINES I (PRAX) stocks. They significantly reduced their stock positions in BIOMARIN PHARMACEUTICAL INC (BMRN), SCHOLAR ROCK HLDG CORP (SRRK) and APOGEE THERAPEUTICS INC. ORBIMED ADVISORS LLC opened new stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), INTEGER HLDGS CORP (ITGR) and ADC THERAPEUTICS SA (ADCT). The fund showed a lot of confidence in some stocks as they added substantially to LYELL IMMUNOPHARMA INC (LYEL), EXACT SCIENCES CORP (EXAS) and VIR BIOTECHNOLOGY INC (VIR).
ORBIMED ADVISORS LLC Equity Portfolio Value
Last Reported on: 14 Aug, 2024

ORBIMED ADVISORS LLC Annual Return Estimates Vs S&P 500

Our best estimate is that ORBIMED ADVISORS LLC made a return of -2.14% in the last quarter. In trailing 12 months, it's portfolio return was 15.12%.

New Buys

Ticker$ Bought
alnylam pharmaceuticals inc60,822,900
integer hldgs corp40,436,300
adc therapeutics sa13,641,200
merus n v9,236,440
c4 therapeutics inc6,990,330
perspective therapeutics inc4,911,920
structure therapeutics inc4,908,750
tg therapeutics inc2,369,630

New stocks bought by ORBIMED ADVISORS LLC

Additions to existing portfolio by ORBIMED ADVISORS LLC

Reductions

Ticker% Reduced
biomarin pharmaceutical inc-97.96
scholar rock hldg corp-69.94
apogee therapeutics inc-47.26
heron therapeutics inc-35.59
geron corp-30.74
janux therapeutics inc-30.31
alx oncology hldgs inc-30.3
avidity biosciences inc-28.93

ORBIMED ADVISORS LLC reduced stake in above stock

Sold off

Ticker$ Sold
esperion therapeutics inc ne-36,739,400
kinnate biopharma inc-21,305,900
perspective therapeutics inc-7,741,900
cytomx therapeutics inc-7,727,180
alpine immune sciences inc-106,255,000
acutus med inc-497,897
ventyx biosciences inc-10,287,500
bolt biotherapeutics inc-2,157,400

ORBIMED ADVISORS LLC got rid off the above stocks

Sector Distribution

ORBIMED ADVISORS LLC has about 78.6% of it's holdings in Healthcare sector.

Sector%
Healthcare78.6
Others19.8
1.6

Market Cap. Distribution

ORBIMED ADVISORS LLC has about 42.1% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
LARGE-CAP30.2
UNALLOCATED20.1
MID-CAP17.4
SMALL-CAP15.8
MEGA-CAP11.9
MICRO-CAP4.5

Stocks belong to which Index?

About 60.8% of the stocks held by ORBIMED ADVISORS LLC either belong to S&P 500 or RUSSELL 2000 index.

Index%
Others39.2
S&P 50032.4
RUSSELL 200028.4
Top 5 Winners (%)%
OMIC
singular genomics systems in
2012.5 %
ALNY
alnylam pharmaceuticals inc
62.1 %
RNA
avidity biosciences inc
43.8 %
THRD
third harmonic bio inc
37.7 %
MRUS
merus n v
26.6 %
Top 5 Winners ($)$
LLY
eli lilly & co
43.1 M
THC
tenet healthcare corp
32.8 M
BSX
boston scientific corp
27.9 M
JANX
janux therapeutics inc
25.1 M
ALNY
alnylam pharmaceuticals inc
23.3 M
Top 5 Losers (%)%
VSTM
verastem inc
-74.8 %
ADGI
invivyd inc
-72.8 %
XFOR
x4 pharmaceuticals inc
-58.3 %
FATE
fate therapeutics inc
-55.3 %
CMPX
compass therapeutics inc
-49.5 %
Top 5 Losers ($)$
XTNT
xtant med hldgs inc
-39.5 M
EVH
evolent health inc
-35.6 M
APLS
apellis pharmaceuticals inc
-26.5 M
KROS
keros therapeutics inc
-26.0 M
SRRK
scholar rock hldg corp
-22.2 M

ORBIMED ADVISORS LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of ORBIMED ADVISORS LLC

ORBIMED ADVISORS LLC has 108 stocks in it's portfolio. About 44% of the portfolio is in top 10 stocks. XTNT proved to be the most loss making stock for the portfolio. LLY was the most profitable stock for ORBIMED ADVISORS LLC last quarter.

Last Reported on: 14 Aug, 2024
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions